Lexicon Pharmaceuticals, Inc.
LXRX
$0.3918
$0.02416.55%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 6.25% | 45.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.25% | 45.75% | |||
| Cost of Revenue | 45.16% | 23.65% | |||
| Gross Profit | -49.12% | -21.77% | |||
| SG&A Expenses | 1.02% | 22.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.81% | 22.68% | |||
| Operating Income | -15.06% | -22.11% | |||
| Income Before Tax | -21.30% | -10.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.30% | -10.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.30% | -10.40% | |||
| EBIT | -15.06% | -22.11% | |||
| EBITDA | -15.13% | -22.19% | |||
| EPS Basic | -4.30% | 12.83% | |||
| Normalized Basic EPS | -4.38% | 12.90% | |||
| EPS Diluted | -4.30% | 12.83% | |||
| Normalized Diluted EPS | -4.38% | 12.90% | |||
| Average Basic Shares Outstanding | 16.30% | 26.67% | |||
| Average Diluted Shares Outstanding | 16.30% | 26.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
